Quartet Medicine is developing therapies that restore BH4 homeostasis to treat chronic pain and inflammatory conditions. Its lead program targets the BH4 synthesis pathway and uses human genetic and BH4-based biomarker tools alongside preclinical models to select early clinical proof-of-concept indications and enable translational biomarker strategies for target engagement. Quartet plans to use the new funding to achieve a near-term development candidate selection milestone and to advance its lead program through early clinical testing over the next two years. The company was founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne in conjunction with Atlas Venture. Quartet is based in Cambridge, Massachusetts and has research collaborators in Europe and Asia. The financing also accompanied Board additions, including John Creecy of Remeditex and Mark Corrigan, M.D., as the company’s first independent Board member. Quartet Medicine focuses on discovering and developing novel treatments that modulate tetrahydrobiopterin (BH4) synthesis to address chronic pain and inflammation. Its lead program targets modulation of BH4 synthesis and is being advanced toward human proof-of-concept studies. The company leverages human genetics and preclinical target-validation data that link BH4 pathway up-regulation to neuronal hypersensitivity and immune cell activation. Quartet aims to safely restore BH4 levels in neuronal and inflammatory cells as a biomarker-driven strategy to translate preclinical pain programs into human trials. Quartet was co-founded by Kevin Pojasek, Clifford Woolf, and Kai Johnsson and has research collaborations in Europe and Asia. The company announced a $17 million Series A to fund progression of its lead program and near-term work toward declaring a development candidate in 2015.

Total raised

$23M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2015